FOLD Amicus Therapeutics: Operatsion rentabellik

Amicus Therapeutics - FOLD emitenti grafik logotipi

Amicus Therapeutics (FOLD) kompaniyasining operatsion marjasi kamyob patologiyalar bo'yicha bemorlarni jalb qilish dinamikasi va patent ko'migi asosida shakllangan bo'lib, ushbu ko'rsatkich 5.40 darajasida qayd etilgan. Joriy daromadlilik Pompe kasalligining yangi davolash usullari uchun sug'urta to'lovlarini ta'minlashdagi qiyinchiliklar tufayli cheklangan. Shunga qaramay, kompaniya og'ir metabolik buzilishlarga qarshi kurashish uchun noyob hayotni saqlovchi dori vositalarini yaratgan holda, mutlaq narx belgilash imkoniyatiga ega.

FOLD: Amicus Therapeutics, Inc. Operatsion marja 04.07.2022 - 09.05.2026

FOLD (Amicus Therapeutics): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning har tomonlama tahlili:Amicus Therapeutics Inc
Amicus Corp tayyor mahsulotlari

Amicus Therapeutics (FOLD) noyob kasalliklar bilan kasallangan bemorlar uchun yopiq terapevtik muhit yaratishni monetizatsiya qiladi, bunda ekotizimning samaradorligi bevosita daromadlilikka ta'sir ko'rsatadi. GURU.Markets platformasida operatsion daromad marjasi sifatida ko'rsatilgan operatsion natijaning tushumga nisbati biznesning moliyaviy xarajatlargacha pul oqimini yaratish qobiliyatini o'lchaydi, bu esa investorlarga kompaniyaning rivojlanish modelining fundamental barqarorligi va kengayuvchanligini baholash imkonini beradi.

Asosiy raqobatchilar

Operatsion rentabellik Ascendis|Madrigal Corp (MDGL) - Operatsion faoliyat rentabelligi|Operatsion rentabellik corcept.com (CORT)|Sotuvning operatsion marjasi rhythmtx.com RYTM|Operatsion marja AKRO (akerotx.com)|MTSR - Sotuvning operatsion marjasi|MLTX - Operatsion rentabellik|Operatsion foyda normasi CRNX (Crinetics Pharma)|NAMS (newamsterdampharma.com) - Sotuvning operatsion marjasi|SLNO (Soleno Therapeutics) - Operatsion rentabellik|Operatsion rentabellik 89bio Pharma|Sotuvning operatsion rentabelligi Agios AGIO|Operatsion marja GPCR|MiMedx Group, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Rezolute Bio - Sotuvning operatsion marjasi|lexpharma.com (LXRX) - Sotuvning operatsion rentabelligi|MBX - Operatsion rentabellik|ALT (Altimmune) - Operatsion foyda bo'yicha sotuv rentabelligi|Aardvark Therapeutics Inc. (AARD) - Operatsion rentabellik|Sagimet - Operatsion foyda normasi|BIOA (BioAge Labs, Inc) - Operatsion marja|Operatsion marja biomeafusion.com|Operatsion marja QNCX|GUTS - Sotuvning operatsion rentabelligi|Operatsion marja VTVT (vTv Therapeutics)|ATPC - Sotuvning operatsion marjasi|PLUR - Operatsion rentabellik|Synlogic Inc. (SYBX) - Sotuvning operatsion marjasi|LPCN (Lipocine Inc) - Sotuvning operatsion marjasi|Matinas BioPharma Holdings, Inc. - Operatsion foyda normasi|SPRB (sprucebiosciences.com) - Operatsion marja|Operatsion rentabellik GLTO|Operatsion marja CTCX|Lumos Pharma, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion marja ONVO (organovo.com)|Operatsion foyda bo'yicha marjinallik Radius Health